Project ACHIEVE, part of Lindsley F. Kimball Research Institute’s Laboratory of Infectious Disease Prevention, is one of multiple research sites involved in the HIV Prevention Trials Network HPTN 083 study. The HIV Prevention Trials Network is a worldwide collaborative clinical trials network that develops and tests the safety and efficacy of interventions designed to prevent the transmission of HIV:

The HIV Prevention Trials Network (HPTN) recently announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men.

View the full HPTN 083 study press release